Supporting document 1
Risk and technical assessment report (at Approval) – Application A1109

Glutaminase from *Bacillus amyloliquefaciens* as a Processing Aid (Enzyme)

**Executive summary**

Application A1109 seeks approval to use the enzyme glutaminase, sourced from a chemically mutated strain of *Bacillus amyloliquefaciens* (strain GT), as a processing aid. The stated purpose of this enzyme is for the production of certain seasoning ingredients (e.g. yeast extract, hydrolysed vegetable proteins and hydrolysed animal proteins) or food products used as seasonings (e.g. soy sauce, miso, vinegar, fish sauce, etc.).

Glutaminase catalyses the conversion of L-glutamine present in these foods to L-glutamate, an important component of taste and quality in the foods to which glutaminase is added. The use of glutaminase to increase the glutamate content of these foods can be an alternative to use of chemicals (acid hydrolysis) or to external sources of glutamate (such as monosodium glutamate (MSG)), to form foods/food ingredients with high concentrations of glutamates.

The evidence presented to support the proposed uses provides adequate assurance that the enzyme, in the form and prescribed amounts, is technologically justified to be effective in achieving its stated purpose. The enzyme preparation meets international purity specifications for enzymes used in the production of food.

There were no public health and safety issues associated with the use of the enzyme preparation, containing glutaminase sourced from a chemically mutated strain of *B. amyloliquefaciens*, as a food processing aid on the basis of the following considerations:

- The production organism is not toxigenic or pathogenic and is not present in the final enzyme preparation used as the food processing aid. Further, *B. amyloliquefaciens* has a history of safe use as the production organism for a number of processing aids already permitted in the *Australia New Zealand Food Standards Code* (the Code).

- Glutaminase has a long history of safe use and although residual enzyme is expected to be present in the final food, it would be susceptible to digestion like any other dietary protein.

- Complete digestion of the enzyme in simulated digestive fluid suggests the enzyme is unlikely to be an allergen.

- Bioinformatic analysis indicated that the enzyme has no biologically relevant homology to known protein toxins or allergens.
• Although there was a reduction in weight gain and feed consumption at the highest
dose tested in a 13-week repeat dose toxicity study in rats, this reduction was
considered to be due to palatability of the feed containing high levels of common table
salt. Thus, in the absence of any treatment related adverse effects, the NOAEL for the
glutaminase concentrate was considered to be at the highest dose tested, which was
2% (w/w) in the diet or 1239 mg/kg bw/day.

• The enzyme was not genotoxic or mutagenic \textit{in vitro}.

Based on the reviewed toxicological data, it was concluded that in the absence of any
identifiable hazard, an Acceptable Daily Intake (ADI) 'not specified' was appropriate. A
dietary exposure assessment was therefore not required.
Table of contents

EXECUTIVE SUMMARY ........................................................................................................... 1

1 INTRODUCTION ..................................................................................................................... 2
  1.1 OBJECTIVES OF THE ASSESSMENT .............................................................................. 2

2 FOOD TECHNOLOGY ASSESSMENT ...................................................................................... 2
  2.1 CHARACTERISATION OF GLUTAMINASE (ENZYME) .................................................. 2
     2.1.1 Identity of the enzyme .......................................................................................... 2
     2.1.2 Enzymatic properties ......................................................................................... 3
     2.1.3 Physical properties ............................................................................................ 3
  2.2 PRODUCTION OF THE ENZYME ................................................................................... 4
     2.2.1 Potential presence of allergens .......................................................................... 4
  2.3 SPECIFICATIONS ........................................................................................................... 4
  2.4 TECHNOLOGICAL FUNCTION OF THE ENZYME .......................................................... 5
  2.5 FOOD TECHNOLOGY CONCLUSION ............................................................................ 5

3 HAZARD ASSESSMENT .......................................................................................................... 6
  3.1 BACKGROUND ............................................................................................................... 6
     3.1.1 Chemistry ......................................................................................................... 6
     3.1.2 Scope of the hazard assessment ....................................................................... 6
  3.2 HAZARD OF THE PRODUCTION ORGANISM – B. AMYLOLIQUEFACIENS STRAIN GT2 .................................................................................................................. 6
  3.3 HAZARD OF THE ENZYME GLUTAMINASE .................................................................. 7
     3.3.1 History of Use ................................................................................................... 7
     3.3.2 Bioinformatic analysis for potential allergenicity .............................................. 7
     3.3.3 Bioinformatic analysis for potential toxicity ..................................................... 7
     3.3.4 Enzyme stability to digestive degradation ........................................................ 8
  3.4 EVALUATION OF TOXICITY STUDIES OF THE ENZYME PRODUCT ....................... 8
     3.4.1 Sub-chronic toxicity .......................................................................................... 8
     3.4.2 Genotoxicity ..................................................................................................... 10
     3.4.3 Residual allergens and substances causing food intolerance from the culture medium .................................................................................................. 11
     3.4.4 Residual enzymes from the production organism ............................................ 11
  3.5 HAZARD ASSESSMENT CONCLUSIONS .................................................................... 11

4 CONCLUSION ......................................................................................................................... 12

5 REFERENCES .......................................................................................................................... 12
1 Introduction

FSANZ received an application from Amano Enzyme Inc. Japan seeking approval for the enzyme glutaminase (EC 3.5.1.2) as a processing aid. The Applicant states that this enzyme will be used in the production of certain seasoning ingredients (e.g. yeast extract, hydrolysed vegetable proteins and hydrolysed animal proteins) or food products used as seasonings (e.g. soy sauce, miso, vinegar, fish sauce, etc.). The enzyme is sourced from a chemically mutated strain of Bacillus amyloliquefaciens strain NP, known as B. amyloliquefaciens strain GT2. Glutaminase sourced from this bacterium is by means of a fermentation process.

The Applicant proposes to use glutaminase to catalyse the conversion of L-glutamine to L-glutamate. L-glutamate enhances the taste of the foods to which the glutaminase is added. The use of glutaminase produced by B. amyloliquefaciens can be an alternative to use of chemicals (acid hydrolysis) or to external sources of glutamate (such as monosodium glutamate (MSG)), to form foods/food ingredients with high concentrations of glutamates.

1.1 Objectives of the Assessment

Currently, there are no permissions for the enzyme glutaminase from B. amyloliquefaciens or any other source in the Code. Therefore, any application to amend the Code to permit the use of this enzyme as a food processing aid requires a pre-market assessment.

The objectives of this risk assessment were to:

- determine whether the proposed purpose is clearly stated and that the enzyme achieves its technological function in the quantity and form proposed to be used as a food processing aid
- evaluate any potential public health and safety concerns that may arise from the use of glutaminase as a processing aid.

2 Food Technology Assessment

2.1 Characterisation of glutaminase (enzyme)

2.1.1 Identity of the enzyme

Information regarding the identity of the enzyme that was taken from the Application has been verified using an appropriate enzyme nomenclature reference (IUBMB, 2015). Additional information has also been included from this reference.

Generic common name: Glutaminase
Systematic name: L-glutamine amidohydrolase
Accepted IUBMB¹ name: Glutaminase
IUBMB enzyme nomenclature: EC 3.5.1.2
C.A.S. number: 9001-47-2

¹ International Union of Biochemistry and Molecular Biology
Other names: glutaminase I; L-glutaminase; glutamine aminohydrolase

Reaction: $L\text{-glutamine} + H_2O = L\text{-glutamate} + NH_3$

Commercial name: Glutaminase SD-C100S

2.1.2 Enzymatic properties

The enzyme glutaminase belongs to the class of hydrolytic enzymes. Its catalytic characteristic is that it catalyses the hydrolysis of the γ-amido bond of $L$-glutamine to $L$-glutamate and ammonia (Nandakumar et al., 2003).

Almost all living cells produce glutaminase, which plays a significant contributory role in cellular nitrogen metabolism. Glutaminase also has important pharmaceutical and industrial uses as an effective agent in the treatment of acute lymphocytic leukaemia and HIV, as an analytical agent, a biosensing agent, as a flavour enhancing agent and in the production of specialty chemicals such as threonine (Sathish & Prakasham, 2010). Microbial glutaminases have a long history of use and are used extensively in the food industry due to their role as flavour-enhancing agents (Sarada, 2013).

The glutaminase enzyme preparation that is the subject of this Application is used for the hydrolysis of the amino acid $L$-glutamine, which is naturally present in the starting food or ingredient, to $L$-glutamate, which is an important component of the quality and taste of the food products to which glutaminase is added (Figure 1). Such food products include seasoning ingredients (e.g. yeast extract, hydrolysed vegetable protein, and hydrolysed animal protein) and food products used as seasonings (e.g. soy sauce, miso, vinegar, and fish sauce).

![Figure 1: Reaction catalysed by glutaminase](image)

The glutaminase enzyme preparation (powder) is active during the manufacture of the glutamine-containing food/food ingredient, with inactivation of the enzyme occurring either by temperature or pH changes. The Applicant recommends that inactivation be accomplished by changing the pH of the food so that it is lower than 5 or greater than 9, or by increasing the temperature above 60°C. This will ensure that the enzyme has no action or function in the final food product.

2.1.3 Physical properties

The commercial enzyme preparation, Glutaminase SD-C100S, is supplied as a light brown powder, comprising 91% (w/w) sodium chloride and 9% (w/w) glutaminase concentrate, and with approximately 86% Total Organic Solids (TOS).

The commercial enzyme preparation shows a glutaminase activity level of 110 glutaminase units (GTU)/gram. The maximum use level of the commercial preparation is 0.2% when used during the manufacture of seasoning ingredients/foods used as seasonings. Based on the dilution of the glutaminase concentrate with sodium chloride, this level of use would be equivalent to 0.018% of the glutaminase concentrate in the final food/food ingredient.
2.2 Production of the enzyme

The glutaminase concentrate is produced by the fermentation of *B. amyloliquefaciens* under standard culturing conditions.

The production steps can be summarised as a fermentation process, a filtration process, production of the glutaminase concentrate, and then formulation of the final commercial glutaminase preparation. The raw materials used in the production of Glutaminase SD-C100S are approved food ingredients, food additives, microbial nutrients, or permitted in the production of processing aids (FSANZ, 2014). The enzyme preparation is reported to be made according to Good Manufacturing Practices.

Once the fermentation is complete, the downstream processing steps consist of several filtration steps. The cultures are filtered twice using high pressure to remove the culture media. This is followed by ultrafiltration to concentrate the extracellular glutaminase, and then one final sterile filtration to remove any remaining bacteria. The resultant concentrate is then spray dried and blended to produce a powdered glutaminase concentrate.

To prepare the commercial enzyme preparation (Glutaminase SD-C100S), the glutaminase concentrate is diluted by the addition of sodium chloride. The Glutaminase SD-C100S preparation comprises 91% sodium chloride and 9% glutaminase concentrate. Some further details of the individual steps are provided in the Application.

2.2.1 Potential presence of allergens

Lactose (which may be produced from whey as a by-product of cheese and casein industries), defatted soybean, soybean oil and dextrin (which may be produced from wheat starch) comprise part of the fermentation medium in the preparation of the glutaminase enzyme. Milk products, soybean products and wheat products are identified as substances requiring declaration in subsection 1.2.3—4(1)(d) of the Code.

2.3 Specifications

There are international specifications for enzyme preparations used in the production of food. These have been established by the Joint FAO/WHO Expert Committee on Food Additives (JECFA, 2016) and the Food Chemicals Codex (Food Chemicals Codex, 2015). These primary sources of specifications are listed in Schedule S3—2 of the Code. Enzyme preparations need to meet these enzyme specifications. Schedule 3 of the Code also includes specifications for heavy metals.

Table 1 provides a comparison of the product specifications with the international specifications established by JECFA as well as those detailed in the Code (as applicable).

<table>
<thead>
<tr>
<th>Analysis</th>
<th>Specifications</th>
<th>Product</th>
<th>JECFA</th>
<th>Australia New Zealand Food Standards Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lead (mg/kg)</td>
<td>≤2</td>
<td>≤ 5</td>
<td>≤2</td>
<td></td>
</tr>
<tr>
<td>Arsenic (mg/kg)</td>
<td>≤1</td>
<td>-</td>
<td>≤1</td>
<td></td>
</tr>
<tr>
<td>Mercury (mg/kg)</td>
<td>≤0.5</td>
<td>-</td>
<td>≤1</td>
<td></td>
</tr>
<tr>
<td>Cadmium (mg/kg)</td>
<td>≤0.5</td>
<td>-</td>
<td>≤1</td>
<td></td>
</tr>
</tbody>
</table>
The Application states that the glutaminase preparation contains no detectable antibiotic activity. Absence of antimicrobial activity is a requirement of the JECFA specifications for enzymes used in food processing.

The final enzyme preparation meets international and Code specifications for enzyme preparations used in the production of food.

### 2.4 Technological function of the enzyme

The enzyme glutaminase, sourced from *B. amyloliquefaciens*, is intended to be used as a processing aid in the production of certain seasoning ingredients (e.g. yeast extract, hydrolysed vegetable protein, and hydrolysed animal protein) or food products used as seasonings (e.g. soy sauce, miso, vinegar, and fish sauce). The enzyme hydrolyses the amino acid L-glutamine in the starting food or ingredient, to L-glutamate, an important flavour component.

Based on information provided by the Applicant, the glutaminase enzyme preparation has benefits that include a high glutamate yield, excellent thermal stability, and stability for at least 12 months when stored according to the recommended conditions.

There are a number of commercial methods available to increase the glutamate content of food products such as those mentioned above. Methods include natural fermentation, acid and base hydrolysis of glutamine-rich proteins, the addition of exogenous enzymes such as proteases, and a combination of these. All of these methods break down proteins in the starting material into individual amino acids, whereby glutamate is an essential element for the distinctive ‘umami’ flavour of these products.

A comparison of enzymatic hydrolysis using glutaminase against other methods for manufacturing certain food products indicates that there are a number of potential advantages. These include milder processing conditions (including milder temperatures), a desirable amino acid profile in the protein hydrolysates due to the specificity of the enzyme, minimal formation of unwanted by-products (such as of mono- and di-chloropropanols), and no neutralisation of the product required after the end of the hydrolysis (Pomeranz, 2013).

### 2.5 Food technology conclusion

The stated purpose of this glutaminase enzyme sourced from *B. amyloliquefaciens*, namely, for use as a processing aid in the production of certain seasoning ingredients (e.g. yeast extract, hydrolysed vegetable protein, and hydrolysed animal protein) or food products used as seasonings (e.g. soy sauce, miso, vinegar, and fish sauce), is clearly articulated in the Application.

---

2 For example, East Asian black vinegar, which is an aged, fermented product made from rice, wheat, millet, sorghum or a combination, and can contain high concentrations of amino acids.

3 The ‘fifth taste’, a pleasant, savoury taste that is full, rounded and with a ‘meaty’ flavour.
The evidence presented to support the proposed uses provides adequate assurance that the enzyme, in the form and prescribed amounts, is technologically justified and has been demonstrated to be effective in achieving its stated purpose. The enzyme preparation meets international purity specifications.

3 Hazard Assessment

3.1 Background

3.1.1 Chemistry

Details of the chemistry of the glutaminase produced by B. amyloliquefaciens, including relevant physicochemical and enzymatic properties, and product specifications, are provided in the Food Technology Assessment (see Section 2).

3.1.2 Scope of the hazard assessment

The hazard of glutaminase sourced from B. amyloliquefaciens was evaluated by considering the:

- hazard of the production organism, including any history of safe use in food production processes
- hazard of the encoded protein, including potential allergenicity
- toxicity studies on the enzyme preparation intended for commercial use.

3.2 Hazard of the production organism – B. amyloliquefaciens strain GT2

The parental lineage of the production organism is classified as B. amyloliquefaciens strain NP. Strain GT2 is a mutant derived from the NP strain by eight rounds of chemical mutagenesis using N-methyl-N'-nitrosoguanidine and selecting for enhanced glutaminase production. Strain GT2 is not genetically modified. This parental strain is neither pathogenic nor toxigenic.

It should be noted that the parent strain (NP) was previously classified as Bacillus subtilis, a species closely related to B. amyloliquefaciens and for which there is also an extensive history of use as a source organism for food products and processing aids in numerous jurisdictions, including Australia and New Zealand (FSANZ, 2014).

The source strain (GT2) is not listed on the American type culture collection (ATCC) or Deutsche Sammlung von Mikroorganismen und Zelkulturen – DSMZ (German Collection of Micro-organisms and Cell Cultures). The applicant provided additional information to establish the taxonomy of the source micro-organism (GT2) and the parent strain (NP). The analysis was performed by TNO Nutrition and Food Research. The microscopy analysis showed that both GT2 and NP were similar to the reference strain B. subtilis ATCC 13933, although all three strains could be differentiated. The biochemical analysis (API 50 CHB) could not satisfactorily identify GT2. The biochemical results for NP gave good identification to the Bacillus genus level but could not satisfactorily identify the strain. The results suggested that NP represents either B. amyloliquefaciens (37.1%), B. licheniformis (36.5%) or B. subtilis (22.3%). Results of the more definitive DNA hybridisation test confirmed the source microorganism (GT2) as B. amyloliquefaciens (95% homology to B. amyloliquefaciens LMG 9814T). DNA hybridisation results were not provided for the parent NP strain.
FSANZ has previously assessed *B. amyloliquefaciens* as a safe production organism for a number of food-grade enzymes. Subsection S18—4(5) of the Code permits the use of the following enzymes derived from *B. amyloliquefaciens* as food processing aids: α-acetolactate, α-amylase, β-amylase, β-glucanase, hemicellulose endo-1,4-xylanase, hemicellulose multicomponent enzyme, metalloprotease, pullulanase and serine proteinase. There have been no reports of allergenicity associated with the use of *B. amyloliquefaciens* in Australia and New Zealand. Additionally, the applicant has reported that since beginning glutaminase production in strain NP in 1992 and strain GT2 in 1997, no adverse effects have been reported in workers exposed to either strain of *B. amyloliquefaciens*.

The European Food Safety Authority (EFSA, 2008) has listed *B. amyloliquefaciens* as a Qualified Presumption of Safety (QPS) organism provided there is evidence around the absence of emetic food poisoning toxins, surfactant activity and enterotoxic activity. The risk clarification derived by the European Community to protect workers exposed to biological agents classifies *B. amyloliquefaciens* in Group 1, meaning it is unlikely to cause human disease (EC, 2000). Additionally, The US FDA established in 1999 that carbohydrase and protease enzyme preparations derived from *B. amyloliquefaciens* or *B. subtilis* were considered Generally Recognized as Safe (GRAS) for use as a direct food additive (US FDA, 2009).

### 3.3 Hazard of the enzyme glutaminase

#### 3.3.1 History of Use

Glutaminase concentrate has been used in Japan for many years in food processing and it is currently on the ‘List of Existing Food Additives’ published by the Ministry of Health and Welfare of Japan (MHLW, 2014). Glutaminase has been employed in the production of soy sauces since 1991 and in the production of miso since 1992 (Amano Enzyme, 2005). The use of glutaminase as a processing aid for the production of hydrolysed vegetable protein has been ongoing since 2003. Glutaminase enzymes sourced from *B. amyloliquefaciens* have a long history of use in Japan as they were first reported in the publicly available literature in 1988 (Shimizu et al., 1991).

#### 3.3.2 Bioinformatic analysis for potential allergenicity

The glutaminase sequence from *B. amyloliquefaciens* was compared via *in silico* analysis with known allergens in two databases, the Allergen Database for Food Safety and Allergen Online. The sequences were compared to identify matches for 8-consecutive amino acids and an 80 amino acid sliding window (with 35% or higher identities within the 80 amino acid stretch). There were no hits (matches) in the search for 8 consecutive amino acids or for the 80 amino acid sliding window in either database. These results indicate that glutaminase does not share any significant amino acid sequence similarity with known food allergens and, therefore, is unlikely to be allergenic.

#### 3.3.3 Bioinformatic analysis for potential toxicity

The applicant provided a bioinformatic study to examine the potential toxicity of the glutaminase enzyme using the Virulence Database, MvirDB, from the Lawrence Livermore National Laboratory, Livermore, California (A1109 Additional information (16 Nov 2015)).

---

4 http://allergen.nih.go.jp/ADFS  
5 http://www.allergenonline.com/databasefasta.shtml  
6 http://mvirdb.llnl.gov/
The database includes not only toxic proteins but all the enzymes expressed by drug resistant or pathogenic bacteria. The search was carried out using default parameters except for the E-value, which was changed from 0.5 to 0.2. The E-value is a measure of the similarity of sequences, the lower the E-value, the higher the congruity of the query amino acid sequence with the database sequence. An E-value of zero would mean that there's an exact match for the amino acid sequence. The homology search revealed hits of approximately 32 to 33% identity between the glutaminase enzyme and two proteins from *Bacillus anthracis*, capD and gamma-glutamyltranspeptidase.

### 3.3.4 Enzyme stability to digestive degradation

The applicant provided a digestion test using simulated digestive fluid at pH 1.2 and 2.0. The test was performed in accordance with the international validation method proposed by the International Life Science Institute (A1109 Additional information (16 Nov 2015)). The glutaminase enzyme was completely digested. Given the long history of safe use of both the production organism and enzyme, the enzyme is unlikely to present any public health and safety issues with regard to allergenicity via oral ingestion.

### 3.4 Evaluation of toxicity studies of the enzyme product

#### 3.4.1 Sub-chronic toxicity


#### 3.4.1.1 Range finding study (study 2054)

A range finding study was conducted over a 14 day period. Observations were made for weight, food conversion, water consumption, organ weight and relative organ weight.

Young albino Wistar rats (Charles River Deutschland, Sulzfeld, Germany) were used for this study; 5 males and 5 females for each treatment. The rats were about 4 weeks old at the start of the study and ranged in size from 127 to 158 g (mean 143 g) for males and from 88 to 126 g (mean 105 g) for females. Feed and water were provided *ad libitum*. The rats were fed a commercial rodent diet (Rat & Mouse No. 3 Breeding Diet, RM3) containing glutaminase (batch number GT70625L12) provided at constant concentrations of 0 (control), 0.2, 0.6 or 2.0% w/w of the diet.

At the high dose (2% w/w), there were significant decreases in mean body weight for males at all observation dates (days 3, 7, 10 and 14) and for females only at day 3. There were no other significant differences for any of the other observations. However, male and female rats of the high-dose group had a general trend of decreased food consumption during the first week of the study and decreased water consumption throughout the study.

#### 3.4.1.2 Sub-chronic study (study 2055)

The sub-chronic study was conducted over 13 consecutive weeks. Clinical observations, growth, food consumption, food conversion efficiency, water consumption, ophthalmoscopy, haematology, clinical chemistry, urinalysis, organ weights, gross examination at autopsy and microscopic examination of various organs were used as criteria for disclosing possible harmful effects.
Young albino Wistar rats (source as above) were used for this study; 20 males and 20 females per treatment. The rats were about 4 weeks old at the start of the study and ranged in size from 139 to 191 g (mean 161 g) for males and 105 to 152 g (mean 124 g) for females. Feed, water and glutaminase dosage were as described above for the range finding study. Results of this study are discussed below.

**Bodyweight gain**

At the highest dose (2.0% w/w), both male and female rats showed a significant decrease in bodyweight gain and feed consumption compared to control animals. The % reduction in mean bodyweight gain was 11% and 17% for males and female rats, respectively.

**Feed & water consumption**

The % reduction in mean feed consumption was 11% and 12% for males and females, respectively. Additionally, feed consumption was statistically significantly decreased in females on the low-dose group at several stages of the study. Transient decreases in water intake were also observed for the high-dose group.

**Blood chemistry**

Blood chemistry showed significant decreases in plasma alkaline phosphatase (ALA) activity (males at mid and high dose and females at high dose), alanine aminotransferase (ALAT) activity (males at mid and high dose and females at high dose). Reductions, rather than elevations, in plasma ALA or ALAT levels are usually not considered to be biologically relevant because they are not associated with any adverse toxicological outcome. The investigators noted the reductions in enzyme activity were not accompanied by any effects on other relevant endpoints, including liver histopathology. There was also a significant decrease in the plasma chloride level in females at the mid-dose group. In the absence of a similar change in the high-dose group, this decrease in chloride in females of the mid-dose group was considered to be unrelated to treatment.

**Organ weights**

For the high-dose group, there were significant decreases in the absolute brain (females), spleen (females), adrenals (females) and liver (males and females) weights; and increases in the relative weights of the testes (males) and brain (females). The investigators have ascribed the increases in the relative weights of the testes and the brain in the high-dose group to the well-known inverse correlation between body weight and the relative weight of these organs. FSANZ concurs with this interpretation. The decreased absolute weights of the spleen, liver and adrenals were not accompanied by any histopathological correlate. There was also a significant increase in the relative weight of the kidneys for female rats in the mid-dose group. This was also considered a fortuitous finding as the kidney weight was normal in the high-dose group.

**Other parameters**

There were no treatment related changes/abnormalities observed in the ophthalmologic, urinalysis, haematological, gross pathology and histopathology tests. There were no deaths or abnormal clinical signs during this study.

**Conclusion**

The investigators of this study considered that the reduced bodyweight gain of the male and female rats in the highest dose group were most likely associated with decreased feed consumption and thus was related to palatability rather than toxicity.
Despite this, they suggested the NOAEL was at the mid-dose level (0.6% w/w). However, the glutaminase mixture contained 91% common table salt, thus rat feed at the highest dose would contain about 1.8% sodium chloride (i.e. 18 g salt per kg of feed), which most likely would affect palatability and therefore consumption of feed. Additionally, there may be small amounts of uncharacterised unpleasant favouring agents coming across from the fermentation process which may also affect palatability. Thus, as it is possible to conclude that bodyweight loss is due to reduced feed intake, the NOAEL is considered to be at the highest test dose (2% w/w), which is equal to a dose of 1239 mg/kg bw/day for male and 1432 mg/kg bw/day for female rats.

3.4.2 Genotoxicity

<table>
<thead>
<tr>
<th>Test</th>
<th>Test system</th>
<th>Test article</th>
<th>Concentration or dose range</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bacterial reverse mutation (Ames test)</td>
<td><em>Salmonella typhimurium</em> strains TA 98, 100, 1535 &amp; 1537</td>
<td>Glutaminase concentrate derived from <em>B. subtilis</em>&lt;sup&gt;1&lt;/sup&gt; (Batch No. GT70625L12)</td>
<td>Test 1 &amp; Test 2: plate incorporation method (62-5000 µg/plate); Test 3: liquid culture method (62-5000 µg/mL)</td>
<td>Negative (+S9)</td>
</tr>
<tr>
<td>Chromosomal aberration test</td>
<td>CHO K-1 cells from Chinese hamster ovaries</td>
<td>As above</td>
<td>Test 1: 0.05-30 µg/mL (+S9); 0.5-200 µg/mL (-S9); Test 2: 0.5-20 µg/mL (+S9); 0.25-60 µg/mL (-S9)</td>
<td>Negative (+S9)</td>
</tr>
</tbody>
</table>

<sup>1</sup> = *B. subtilis* has been reclassified as *B. amyloliquefaciens* (see section 3.2)

The results of these unpublished *in vitro* studies are summarised in Table 2. Positive and negative (vehicle) controls were tested in each study and gave expected results. The reverse mutation study comprised three experiments involving either the plate incorporation method (solid medium) or liquid culture methods. The chromosomal aberration study comprised two experiments that involved two different exposure times and different dose concentrations. It is concluded that the glutaminase preparation did not induce gene mutations or chromosome aberrations in these assays.

Table 2: Summary of genotoxicity studies

<table>
<thead>
<tr>
<th>Test</th>
<th>Test system</th>
<th>Test article</th>
<th>Concentration or dose range</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bacterial reverse mutation (Ames test)</td>
<td><em>Salmonella typhimurium</em> strains TA 98, 100, 1535 &amp; 1537</td>
<td>Glutaminase concentrate derived from <em>B. subtilis</em>&lt;sup&gt;1&lt;/sup&gt; (Batch No. GT70625L12)</td>
<td>Test 1 &amp; Test 2: plate incorporation method (62-5000 µg/plate); Test 3: liquid culture method (62-5000 µg/mL)</td>
<td>Negative (+S9)</td>
</tr>
<tr>
<td>Chromosomal aberration test</td>
<td>CHO K-1 cells from Chinese hamster ovaries</td>
<td>As above</td>
<td>Test 1: 0.05-30 µg/mL (+S9); 0.5-200 µg/mL (-S9); Test 2: 0.5-20 µg/mL (+S9); 0.25-60 µg/mL (-S9)</td>
<td>Negative (+S9)</td>
</tr>
</tbody>
</table>

<sup>1</sup> = *B. subtilis* has been reclassified as *B. amyloliquefaciens* (see section 3.2)
3.4.3 Residual allergens and substances causing food intolerance from the culture medium

Soybean oil, defatted soybean, lactose and dextrin (which may be derived from wheat starch) comprise part of the fermentation medium in the preparation of the glutaminase enzyme. However, residual soy or wheat allergens and lactose that may cause food allergy are not expected to be present in the final commercial product. Glutaminase SD-C100S is proposed for use at 0.2% during manufacture of seasoning ingredients/foods used as seasonings and, as the product is 9% glutaminase, this is equivalent to 0.018% of the glutaminase concentrate in the seasoning. These seasonings (e.g. yeast extracts, soy sauce, miso, vinegar, fish sauce etc.) are typically added at low levels to other food products. As stated in Section 2.2, all the raw materials used in the production of Glutaminase SD-C100S are approved food ingredients, food additives, microbial nutrients, or permitted in the production of processing aids (FSANZ, 2014).

3.4.4 Residual enzymes from the production organism

During production, glutaminase is secreted by *B. amyloliquefaciens* during the fermentation process. However, there are other enzymes in the glutaminase concentrate and the final glutaminase preparation: α-amylase, protease and peptidase. Supporting studies (Appendix A) show that the peptidase activity was difficult to confirm and was below the detection limit and, therefore, the applicant has indicated it does not have a function in the manufacturing process. The applicant indicated via correspondence that the protease is a metalloproteinase. Both α-amylase and the protease (metalloproteinase) sourced from *B. amyloliquefaciens* are approved under Standard 1.3.3.

3.5 Hazard assessment conclusions

There are no public health and safety issues associated with the use of Glutaminase SD-C100S, containing glutaminase produced by *B. amyloliquefaciens*, as a food processing aid on the basis of the following considerations:

- The production organism is not toxigenic or pathogenic and is not present in the final enzyme preparation used as the food processing aid. Further, *B. amyloliquefaciens* has a history of safe use as the production organism for a number of processing aids already permitted in the Code.

- Glutaminase has a long history of safe use and although residual enzyme is expected to be present in the final food, it would be susceptible to digestion like any other dietary protein.

- Complete digestion of the enzyme in simulated digestive fluid suggests the enzyme is unlikely to be an allergen.

- Bioinformatic analysis indicated that the enzyme has no biologically relevant homology to known protein toxins or allergens.

- Although there was a reduction in weight gain and feed consumption at the highest dose tested in a 13-week repeat dose toxicity study in rats, this reduction was considered to be due to palatability of the feed containing high levels of common table salt. Thus, in the absence of any treatment related adverse effects, the NOAEL for the glutaminase concentrate was considered to be at the highest dose tested, which was 2% (w/w) in the diet or 1239 mg/kg bw/day.
The enzyme was not genotoxic or mutagenic *in vitro.*

Based on the reviewed toxicological data, it was concluded that in the absence of any identifiable hazard, an Acceptable Daily Intake (ADI) 'not specified' was appropriate. A dietary exposure assessment was therefore not required.

**4 Conclusion**

This risk assessment considered the technological suitability, potential hazard of the production microorganism and the potential hazard of the enzyme glutaminase.

It was concluded that the proposed use of the enzyme was technologically justified in the form and prescribed amounts, and was demonstrated to be effective. The evidence presented was sufficient to determine that no safety concerns with the production microorganism or the enzyme exist. Thus the enzyme glutaminase sourced from *B. amyloliquefaciens* is unlikely to pose any health risk when used as a food processing aid.

**5 References**


EFSA (2008) Opinion of the Panel on Biological Hazards on the maintenance of the list of QPS microorganisms intentionally added to food or feed. The EFSA Journal 923: 1-48.


IUBMB (2015) EC 3.5.1.2. [http://www.enzyme-database.org/query.php?name=3.5.1.2&search=search_all&display=show_all&order=ec_num&nr=50](http://www.enzyme-database.org/query.php?name=3.5.1.2&search=search_all&display=show_all&order=ec_num&nr=50).


